Last reviewed · How we verify
NeoMTA
NeoMTA is a bioactive dental material that promotes mineralization and biocompatibility through calcium and hydroxide ion release.
NeoMTA is a bioactive dental material that promotes mineralization and biocompatibility through calcium and hydroxide ion release. Used for Endodontic applications including pulp capping and apical barrier formation, Periapical lesion treatment, Root perforation repair.
At a glance
| Generic name | NeoMTA |
|---|---|
| Sponsor | Texas A & M University Baylor College Of Dentistry |
| Drug class | Dental biomaterial / Bioactive cement |
| Modality | Biologic |
| Therapeutic area | Dentistry / Endodontics |
| Phase | FDA-approved |
Mechanism of action
NeoMTA is a nanoparticle-modified mineral trioxide aggregate (MTA) formulation designed for endodontic and restorative dental applications. It combines the bioactive properties of traditional MTA with improved handling characteristics and enhanced biocompatibility. The material releases calcium ions that promote remineralization and create an alkaline environment conducive to healing.
Approved indications
- Endodontic applications including pulp capping and apical barrier formation
- Periapical lesion treatment
- Root perforation repair
Common side effects
Key clinical trials
- Direct Pulp Capping Versus Pulpotomy for Primary Molars (NA)
- Clinical and Radio-graphic Evaluation of Non-staining Bio-active Bio-ceramic (Neo MTA 2) in Revascularization (PHASE2)
- Efficacy Of Proinflammatory Cytokines in The Primary Molar Pulpotomy (NA)
- Outcomes of NeoMTA and NeoPUTTY Pulpotomies in Primary Molars (NA)
- Assessment of Pulpotomy Procedure Using NeoMTA Plus in Permanent Teeth With Carious Exposure (NA)
- Assessment of Vital Pulp Therapy in Permanent Molars (NA)
- Clinical & Radiographic Evaluation of Neo MTA Versus White MTA in Revascularization of Non-Vital Immature Permanent Teeth (EARLY_PHASE1)
- Evaluation of Clinical and Radiological Success of Vital Amputation Treatment (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |